Mifepristone administered as pellets (6 mg; Fig. 2A) or as subcutaneous daily doses of 12 mg/kg body weight (Wargon et al. 2009) induced complete regression of ER+ PR+ mammary carcinomas with higher levels of PRA than PRB (Lanari et al. 2009). Here, RB1 is linked to breast carcinoma.